Redeye retains its positive view on Proact following a mixed Q1 report with a solid outlook.
Redeye changes our short-term estimates on the back of a challenging environment for Tagmaster.
Redeye does limited changes to estimates following Evolution’s Q1-results which came in close to our...
Sales 0% vs ABGSCe Adj. EBITA 12% vs ABGSCe Europe and RoW driving growth, Nordics more muted Q1’2...
Redeye concludes that Q1 was weaker than Redeye estimates.
Sales up 29% y-o-y, but pressured profitability Write down of account receivable of SEK 15m due to U...
Redeye has a positive initial take on the Q1 report – SaaS KPIs confirm that Artificial Solutions is...
Biovica has now submitted the updated FDA application.
Sdiptech delivered a solid Q1 report, in line with our expectations on EBITA*, but -4% on the report...
Redeye states that the Q4 report was mixed with better sales development and weaker profitability.
Continued strong backlog build-up, bank amendment China production expected to resume mid-May Small ...
Adj. EBITA 12% above ABGSCe Strong order intake continues, up 28% y-o-y Estimates should stay intact...
Q1 EBIT was SEK 145m Pulp prices in Europe back to all-time highs Fair value range of SEK 10-15/shar...
Price hikes and cost savings the theme in Q1 Confident message regarding debt levels We raise our ‘2...
Seasonally softer, but volumes up 6x y-o-y Continued geographical expansion to support volumes We ma...
Expecting sales of SEK 875-925m (vs ABGSCe 871m) … … and adj.
Q1: solid sales momentum, offset by costs near-term ALS acquisition not closed yet 2025 ambitions im...
Omicron softens installations and orders in Q1’22e Sales down 3-2% ’22-24e on FX and supply chain Hi...
Redeye concludes that Q1 was weaker than our expectations.
Redeye argues that the preliminary sales figure reported by Ngenic today was slightly lower than our...
